Abstract:Objectives Anthocyanin (ACN) is a natural polyphenol with anti-diabetic effects. However, intact anthocyanin has low bioavailability and largely arrives unmetabolized in the colon, its mechanisms of action remain unclear. The intestinal microbiota dysbiosis and leaky gut contribute to the development of diet-induced type 2 diabetes. Therefore, we aim to investigate whether the anti-diabetic effects of anthocyanin were related to changes in the gut microbiota and epithelial barrier function. Methods Male C57Bl/6 N mice were randomly assigned into 4 groups and pair-fed either a chow or high fat/high sugar diet (HFHS, 45 kcal% fat, 17 kcal% sucrose) +/- 1.0% anthocyanin for 8 weeks. Indices of systemic inflammation, parameters of glucose homeostasis and intestinal barrier function were determined. The composition of the gut microbiota was assessed by analysing 16S rRNA gene sequences with Illumina pyrosequencing. To ascertain the involvement of the gut microbiota in the anti-diabetic effects of anthocyanin. A separate cohort of HFHS-fed C57Bl/6 N mice were oral gavage administered with fecal microbiota from chow-fed donors, HFHS-fed donors, HFHS + ACN-fed donors and heat-killed fecal microbial from HFHS + ACN-fed donors (HK-ACN) for 8 weeks, followed by the same examination. Results Relative to vehicle controls, ACN ingestion attenuated several effects of HFHS feeding, including glucose intolerance, insulin resistance and serum inflammatory markers. ACN ingestion reduced intestinal permeability and metabolic endotoxemia. These beneficial effects of ACN were associated with increased expression of genes involved in epithelial barrier function (ZO-1, occludin) and decreased inducible NO-synthase (iNOS) protein levels in ileum and colon of HFHS-fed mice. Gut microbiota analysis revealed that ACN ingestion induced profound alterations in the gut microbiome of HFHS-fed mice. Transplantation of the gut microbiome from ACN-fed mice, but not HFHS-fed or HK-ACN-fed mice, was sufficient to recapitulate the improvement in intestinal epithelial barrier function, systemic inflammation and glucose homeostasis observed with oral ACN treatment. Conclusions These findings indicate that ACN-mediated changes in the gut microbiota and epithelial barrier function may play a predominant role in the mechanism of action of anthocyanin. Funding Sources The State Key Program of National Natural Science Foundation of China [grant number 81730090].

Anthocyanins Increase Serum Adiponectin in Newly Diagnosed Diabetes but Not in Prediabetes: a Randomized Controlled Trial

Anthocyanins Regulate Serum Adipsin and Visfatin in Patients with Prediabetes or Newly Diagnosed Diabetes: a Randomized Controlled Trial

Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients.

Role of Purified Anthocyanins in Improving Cardiometabolic Risk Factors in Chinese Men and Women with Prediabetes or Early Untreated Diabetes—A Randomized Controlled Trial

Effect of Anthocyanins Supplementation on Serum IGFBP-4 Fragments and Glycemic Control in Patients with Fasting Hyperglycemia: A Randomized Controlled Trial

Anthocyanin Increases Adiponectin Secretion and Protects Against Diabetes-Related Endothelial Dysfunction.

Effects of anthocyanin supplementation in diet on glycemic and related cardiovascular biomarkers in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Anthocyanins' effects on diabetes mellitus and islet transplantation.

A Dose-Response Evaluation of Purified Anthocyanins on Inflammatory and Oxidative Biomarkers and Metabolic Risk Factors in Healthy Young Adults: A Randomized Controlled Trial

Anthocyanin Supplementation Improves Anti-Oxidative and Anti-Inflammatory Capacity in a Dose–response Manner in Subjects with Dyslipidemia

Anthocyanin Supplementation at Different Doses Improves Cholesterol Efflux Capacity in Subjects with Dyslipidemia—a Randomized Controlled Trial

A CONSORT-compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients with Nonalcoholic Fatty Liver Disease.

Anti-inflammatory Effect of Purified Dietary Anthocyanin in Adults with Hypercholesterolemia: A Randomized Controlled Trial

Anthocyanins and Type 2 Diabetes: An Update of Human Study and Clinical Trial

Anthocyanin Improves Glucose Homeostasis in Obese Mice Via Beneficial Regulation of Intestinal Microbiota and Barrier Function (OR34-08-19).

The update of anthocyanins on obesity and type 2 diabetes: Experimental evidence and clinical perspectives

Anthocyanin Supplementation Improves Serum LDL- and HDL-cholesterol Concentrations Associated with the Inhibition of Cholesteryl Ester Transfer Protein in Dyslipidemic Subjects.

Change Of Plasma Metabolites In Response To Omega-3 Fatty Acids In Chinese Patients With Type 2 Diabetes: A Double-Blinded Randomized Controlled Trial

Dose-dependent reductions in plasma ceramides after anthocyanin supplementation are associated with improvements in plasma lipids and cholesterol efflux capacity in dyslipidemia: A randomized controlled trial.

Effect of Acylated and Nonacylated Anthocyanins on Urine Metabolic Profile During the Development of Type 2 Diabetes in Zucker Diabetic Fatty Rats.